Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

Overview of attention for article published in BMC Cancer, July 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 43 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 53,032 followers.

RT @MedBunker: @stemagno74 @lucadf Ne ho parlato pure nel mio ultimo libro, citando il caso del Tarceva. https://t.co/eccQMHKZTZ e se si co…

03 Jul 2018

Reply Repost Favourite

RT @MedBunker: @stemagno74 @lucadf Ne ho parlato pure nel mio ultimo libro, citando il caso del Tarceva. https://t.co/eccQMHKZTZ e se si co…

02 Jul 2018

Reply Repost Favourite

@stemagno74 @lucadf Ne ho parlato pure nel mio ultimo libro, citando il caso del Tarceva. https://t.co/eccQMHKZTZ e se si considerano anche i costi e la spesa pubblica è un delirio.

02 Jul 2018

Reply Repost Favourite

RT @lgoodbu: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer - https://t.co/KqarpSHvGf #GoogleAlerts

13 Jul 2016

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.